Use of high-flow nasal cannula oxygen and risk factors for high-flow nasal cannula oxygen failure in critically-ill patients with COVID-19

Table 3 Risk factors for high-flow nasal cannula oxygen therapy failure

Variables	Landmark 48 h risk set (n = 72)			Landmark 72 h risk set (n = 53)
Variables	CSH	95%CI	p value	CSH	95%CI	p value
SAPS-2 score (+ 10 points)	1.55	1.26–1.92	< 0.001	1.60	1.21–2.13	< 0.001
CT-Scan abnormalities > 75%	28.94	3.14–266.02	0.003	10.48	1.92–118.22	0.03
6-h ROX index (+ 1 point)	0.92	0.44–2.28	0.85	0.98	0.47–3.76	0.58
HFNC duration from landmark (+ 1 day)*	0.11	0.04–0.28	< 0.001	0.06	0.02–0.23	< 0.001

Covariables included in the landmark time-dependent cause-specific Cox proportional hazard model before stepwise covariate selection: Age; SAPS-2 score; Body mass index; Intensity of thrombophylaxis; extent of CT-Scan abnormalities > 75%; Lymphocytes count; Fibrinogen level; D-Dimer level; Interleukin-6 level; Corticosteroids administration; Immunomodulatory treatments administration; Antiviral drugs administration; Antibiotherapy administration; 6-h ROX index; HFNC duration and delay from onset of symptoms to HFNC initiation
CI confidence interval, CSH cause specific hazard ratio, HFNC high-flow nasal cannula oxygen therapy, SAPS simplified acute physiology score
*Time-dependent covariate: 38 patients had HFNC failure for the 48 h analysis and 28 patients had HFNC failure for the 72 h analysis

ISSN: 1465-993X